Hanmi Pharmaceutical (128940) announced on the 23rd that the International Nonproprietary Name (INN) for 'HM15275', its next-generation triple-acting obesity treatment, has been finalized as 'zantrutide'.

The World Health Organization (WHO) establishes and registers international nonproprietary names to prevent confusion among pharmaceutical products and to help researchers, medical professionals, and regulatory agencies share drug information more easily.

Choi In-young, Executive Vice President and Head of the R&D Center at Hanmi Pharmaceutical, stated, "It is meaningful that Hanmi's promising R&D asset has secured a globally accepted name, enhancing its future value and recognition as a global new drug asset."

Zantrutide is a pipeline developed through Hanmi's obesity new drug project, 'H.O.P'.

It is a next-generation triple agonist designed to optimize the receptor actions of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) to achieve weight loss while exerting therapeutic effects on various metabolic diseases.

Hanmi Pharmaceutical explained that this substance aims for a weight loss effect of more than 25% and minimization of muscle loss.

Phase 2 clinical trials targeting obesity and diabetes are currently underway in the United States. Hanmi Pharmaceutical expects the Phase 2 clinical trial for obesity to conclude in the first half of next year.

[Copyright (c) Global Economic Times. All Rights Reserved.]